Analysis – Page 2 – Goldea Capital

Man Group PLC : Form 8.3 – JTC Plc

Written by Customer Service on February 13, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree JTC Plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure,...

The Marketing Alliance Announces Financial Results for Fiscal Third Quarter Ended December 31, 2025

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

ST. LOUIS, Feb. 13, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 third quarter ended December 31, 2025. Q3 FY2026 Financial Key Items (all comparisons to the prior year quarter)Revenues from operations were $5,018,127 compared to $4,550,421, an increase of over 10% which was driven by an increase in revenue from the insurance distribution business Operating income from continuing operations of $299,637 compared to $(124,345) in the prior year quarter Net income was $268,692 or $0.04 per share in the quarter compared to $(164,867) or $(0.02) per share in the prior year quarter During the quarter the Company repurchased 117,962 shares, and subsequent to the end of quarter the Company has repurchased an additional 295,959 shares...

Titanium Files Management Information Circular for Special Meeting of Shareholders and Confirms Receipt of Interim Order for Previously-Announced Going-Private Transaction

Written by Customer Service on February 13, 2026. Posted in Public Companies.

Key highlights:The Board of Directors of Titanium (with interested directors abstaining from voting), acting on the unanimous recommendation of the Special Committee, unanimously recommends that Shareholders (other than Rolling Shareholders) vote FOR the Transaction.Shareholders are encouraged to vote well in advance of the proxy voting deadline of Friday, March 6, 2026 at 9:00 a.m. (Toronto time).Shareholders who have questions or need assistance with voting their shares should contact Titanium’s proxy solicitation agent and shareholder communications advisor, Laurel Hill Advisory Group, by email at assistance@laurelhill.com or by texting “INFO” to, or calling, 1-877-452-7184 (North American toll-free) or 1-416-304-0211 (outside North America).BOLTON, Ontario, Feb. 13, 2026 (GLOBE NEWSWIRE) — Titanium Transportation Group...

Candid and Idealist Announce Job Listings Partnership

Written by Customer Service on February 13, 2026. Posted in Mergers And Acquisitions.

Idealist to support more job seekers and nonprofits, taking on Philanthropy News Digest’s job service New York, NY, Feb. 13, 2026 (GLOBE NEWSWIRE) — Candid and Idealist, two nonprofits that serve the social-impact sector through tools for insights and connection, announced an agreement that will transfer Philanthropy News Digest’s job service to Idealist, providing a way for nonprofits and nonprofit professionals to continue benefiting from sector-specific opportunities to advertise and find open positions. Candid, formed in 2019 when GuideStar and Foundation Center merged, provides the most comprehensive data and insights about the social sector. Idealist, founded in 1996, serves millions of people looking for ways to build a better world, through full-time jobs, internships, volunteerism, and connecting with neighbors to address...

Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors

Written by Customer Service on February 13, 2026. Posted in Public Companies.

SOUTH ORANGE, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) — Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced its entry into the Puerto Rican market, targeting high-need applications such as ice machines, drinking fountains, bottle fillers, and sterile processing environments. With a proven track record in infection control and water purity, Nephros brings a differentiated approach to water filtration, delivering advanced products with faster service and local-language support in a region long underserved by premium filtration providers. Puerto Rico MarketWith increasing focus on public health, waterborne pathogen risk, and infrastructure-driven water quality challenges, Nephros believes its infection-control filtration solutions serve...

Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent DevelopmentsResearch and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines. Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and Asia.“We continue to see positive momentum in our sales pipeline across our global markets year-to-date in fiscal year 2026. Customers in...

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data for MDNA11 demonstrates compelling activity in earlier-line expansion cohorts Among expansion cohorts treated with MDNA11 as a 2L or3L systemic treatment or as the next treatment following resistance to checkpoint therapy, MDNA11 demonstrated an objective response rate (“ORR”) of 36% (N=14) in the monotherapy setting and 43% (N=14) when combined with pembrolizumab The ABILITY-1 study has added a new expansion cohort where patients with non-small cell lung cancer (NSCLC) and secondary resistance to checkpoint therapy will be treated with MDNA11 in combination with pembrolizumab, potentially addressing the needs for one...

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Written by Customer Service on February 13, 2026. Posted in Earnings Releases And Operating Results.

– Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events –– Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 – This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — HELUS PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today reported unaudited financial results for its third quarter ended December 31, 2025, and recent business highlights. “The...

Opus Genetics Announces $25 Million Private Placement

Written by Customer Service on February 13, 2026. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has entered into a securities purchase agreement for a private placement (the “private placement”) of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share. Subject to Opus Genetics stockholder approval of an increase to the authorized shares of common stock sufficient to permit the conversion, each share of Series B Non-Voting Convertible Preferred Stock will automatically convert into one share of common stock for an aggregate of 7,374,632 shares of common stock. The...

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Written by Customer Service on February 13, 2026. Posted in Public Companies.

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air’s subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026 Conference call at 8:00 a.m. ET today, February 13th GARDEN CITY, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc....

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals